Effect of Ketoconazole on Biliary Excretion of AZD0837
An Open, Randomised, Cross-over, Single Centre Pharmacokinetic (Phase I) Study of the Biliary Excretion Following Single Doses of AZD0837, Given in the Duodenum Via a Loc-I-Gut Catheter, Alone or in Combination With Ketoconazole (Once Daily for 4 Days), to Young Healthy Male Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive
Exclusion Criteria:
- Significant illness, trauma or surgical procedures.
- Clinically significant laboratory abnormalities.
- Clinically significant medical history
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
Oral solution, dosing through the Loc-I-Gut catheter, single dose
|
|
Active Comparator: 2
AZD0837 + Ketoconazole
|
Oral solution, dosing through the Loc-I-Gut catheter, single dose
tablets, orally, once daily for 3 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Amount of AZD0837, AR-H069927XX, and AR-H067637XX in bile and biliary clearance of AZD0837, AR-H069927XX, and AR-H067637XX.
Time Frame: Frequent sampling through a Loc-I-Gut catheter for up to 3 hours post dose.
|
Frequent sampling through a Loc-I-Gut catheter for up to 3 hours post dose.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PK variables of AZD0837, AR-H069927XX, and AR-H067637XX.
Time Frame: Frequent sampling during 24 hours.
|
Frequent sampling during 24 hours.
|
|
Adverse events, physical examination, safety laboratory variables, blood pressure, pulse and electrocardiography.
Time Frame: Some of the safety variables will be followed at each visit, some less frequent.
|
Some of the safety variables will be followed at each visit, some less frequent.
|
|
Pharmacogenetics
Time Frame: One sampling during the study.
|
One sampling during the study.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Ketoconazole
Other Study ID Numbers
Other Study ID Numbers
- D1250C00029
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.